Glibenclamid-Horm 3,5

Hauptinformation

  • Handelsname:
  • Glibenclamid-Horm 3,5 Tablette
  • Darreichungsform:
  • Tablette
  • Zusammensetzung:
  • Glibenclamid 3.5mg
  • Verwenden für:
  • Menschen
  • Art der Medizin:
  • allopathic Droge

Dokumenten

  • für die Allgemeinheit:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie das Informationsblatt für die Öffentlichkeit.

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Glibenclamid-Horm 3,5 Tablette
    Deutschland
  • Sprache:
  • Deutsch

Weitere Informationen

Status

  • Quelle:
  • BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte
  • Zulassungsnummer:
  • 3617.00.00
  • Letzte Änderung:
  • 02-12-2018

23-11-2018

„Bisphosphonat-Therapie mit Zolendronat oder Clodronat beim Mammakarzinom“

„Bisphosphonat-Therapie mit Zolendronat oder Clodronat beim Mammakarzinom“

Bewertung zur „Bisphosphonat-Therapie mit Zolendronat oder Clodronat bei postmenopausalen Patientinnen mit einem Hormonrezeptor (HR)-positivem, HER2-negativem Mammakarzinom “

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

21-6-2018

Bisphosphonat-Therapie mit Zolendronat oder Clodronat (in der tumorspezifischen Therapie zusätzlich zur adjuvanten antihormonellen Therapie mit Aromataseinhibitoren oder Tamoxifen) bei postmenopausalen Patientinnen mit einem Hormonrezeptor (HR)-positivem,

Bisphosphonat-Therapie mit Zolendronat oder Clodronat (in der tumorspezifischen Therapie zusätzlich zur adjuvanten antihormonellen Therapie mit Aromataseinhibitoren oder Tamoxifen) bei postmenopausalen Patientinnen mit einem Hormonrezeptor (HR)-positivem,

Bisphosphonat-Therapie mit Zolendronat oder Clodronat (in der tumorspezifischen Therapie zusätzlich zur adjuvanten antihormonellen Therapie mit Aromataseinhibitoren oder Tamoxifen) bei postmenopausalen Patientinnen mit einem Hormonrezeptor (HR)-positivem, HER2-negativem Mammakarzinom (ohne Fernmetastasen, M0)

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

12-6-2018

Dave’s Pet Food Voluntarily Recalls 95% Premium Beef Canned Dog Food Due to Potentially Elevated Levels of Thyroid Hormone

Dave’s Pet Food Voluntarily Recalls 95% Premium Beef Canned Dog Food Due to Potentially Elevated Levels of Thyroid Hormone

Dave’s Pet Food of Agawam, MA is recalling a single lot of Dave’s Dog Food 95% premium beef cans because the products potentially contain elevated levels of beef thyroid hormone.

FDA - U.S. Food and Drug Administration

29-5-2018

TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) by Allergan: Recall - Due to Out of Sequence Capsules

TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) by Allergan: Recall - Due to Out of Sequence Capsules

Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal placebo capsules instead of active capsules. As a result of this packaging error, oral contraceptive capsules, that are taken out of sequence, may place the user at risk for contraceptive failure and unintended pregnancy. The reversing of the order may not be apparent to either new users or previous ...

FDA - U.S. Food and Drug Administration

29-5-2018

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

Allergan plc (NYSE:AGN) today issued a voluntary recall in the US market of one lot (Lot# 5620706, Expiry May-2019) of TAYTULLA® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, 6x28 physicians sample pack, indicated for use by women to prevent pregnancy. Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal...

FDA - U.S. Food and Drug Administration

23-5-2018

Merrick Pet Care Voluntarily Recalls Limited Amount of Good Buddy and Backcountry Treats Containing Beef Due to Potentially Elevated Levels of Thyroid Hormone

Merrick Pet Care Voluntarily Recalls Limited Amount of Good Buddy and Backcountry Treats Containing Beef Due to Potentially Elevated Levels of Thyroid Hormone

Merrick Pet Care, of Amarillo, Texas, is initiating a voluntary recall of a limited amount of beef dog treat varieties due to the potential that they contain elevated levels of a naturally-occurring beef thyroid hormone.

FDA - U.S. Food and Drug Administration

6-5-2014

Guidance material to doctors and users of contraceptive pills

Guidance material to doctors and users of contraceptive pills

The EU Pharmacovigilance Risk Assessment Committee (PRAC) recently completed a review of the risk of blood clots (VTE) with contraceptive pills and other combined hormonal contraceptives. Combined hormonal contraceptives contain two types of hormone, oestrogen and progesterone, and are available as pills, transdermal patches and vaginal rings.

Danish Medicines Agency

4-1-2019


Orphan designation: Glibenclamide for the treatment of neonatal diabetes, Treatment of neonatal diabetes, 15/01/2016, Positive

Orphan designation: Glibenclamide for the treatment of neonatal diabetes, Treatment of neonatal diabetes, 15/01/2016, Positive

Orphan designation: Glibenclamide for the treatment of neonatal diabetes, Treatment of neonatal diabetes, 15/01/2016, Positive

Europe - EMA - European Medicines Agency

19-12-2018


Orphan designation: Somapacitan, Treatment of growth hormone deficiency, 24/08/2018, Positive

Orphan designation: Somapacitan, Treatment of growth hormone deficiency, 24/08/2018, Positive

Orphan designation: Somapacitan, Treatment of growth hormone deficiency, 24/08/2018, Positive

Europe - EMA - European Medicines Agency

31-10-2018

Quetiapin-Hormosan Filmtabletten

Rote - Liste

28-9-2018

Glibenclamid AbZ Tabletten

Rote - Liste

17-9-2018

Sumatriptan-Hormosan Filmtabletten

Rote - Liste

12-9-2018

Quetiapin-Hormosan Retardtabletten

Rote - Liste

30-8-2018

Lamotrigin-Hormosan

Rote - Liste

16-8-2018

Rasagilin-Hormosan 1 mg Tabletten

Rote - Liste

13-8-2018

Rivastigmin-Hormosan Hartkapseln

Rote - Liste

6-8-2018

Topiramat-Hormosan

Rote - Liste

16-7-2018

Valsartan-Hormosan Filmtabletten

Rote - Liste

16-7-2018

Tadalafil-Hormosan 5 mg Filmtabletten

Rote - Liste

5-6-2018

Levetiracetam-Hormosan Filmtabletten

Rote - Liste

28-5-2018

AMGLIDIA (AMMTeK)

AMGLIDIA (AMMTeK)

AMGLIDIA (Active substance: glibenclamide) - Centralised - Authorisation - Commission Decision (2018)3341 of Mon, 28 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4379

Europe -DG Health and Food Safety

28-5-2018

Sildenafil-Hormosan Filmtabletten

Rote - Liste

21-3-2018

EU/3/16/1671 (IQVIA RDS Ireland Limited)

EU/3/16/1671 (IQVIA RDS Ireland Limited)

EU/3/16/1671 (Active substance: 2'-O-(2-methoxyethyl)phosphorothioate antisense oligonucleotide targeting the growth hormone receptor) - Transfer of orphan designation - Commission Decision (2018)1821 of Wed, 21 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/023/16/T/01

Europe -DG Health and Food Safety

23-2-2018

Pending EC decision:  Amglidia, glibenclamide, Opinion date: 22-Feb-2018

Pending EC decision: Amglidia, glibenclamide, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency